Case study #8: Alpha-therapy with radium-223 dichloride for metastatic castration-resistant prostate cancer Book Section
| Authors: | Pasquini, L.; Morris, M. J.; Bodei, L. |
| Editors: | Bodei, L.; Lewis, J. S.; Zeglis, B. M. |
| Article/Chapter Title: | Case study #8: Alpha-therapy with radium-223 dichloride for metastatic castration-resistant prostate cancer |
| Abstract: | Metastatic spread to the bones is a leading cause of mortality in patients with prostate cancer. Radiopharmaceutical therapy (RPT) has been used as part of several different treatment strategies for metastatic castration-resistant prostate cancer (mCRPC). Radium-223 dichloride-[223Ra]RaCl2-is currently used both alone and in combination therapies for mCRPC with bone involvement and no bulky visceral metastatic disease. The alpha particle-emitting radiotherapeutic accumulates in the vicinity of activated osteoblasts and within the surrounding bone matrix, irradiating nearby cancer cells with minimal bone marrow toxicity. This treatment has demonstrated palliative effects for bone pain as well as proven benefits for overall survival. In this chapter, we summarize the biochemistry, dosimetry, and clinical development of [223Ra]RaCl2 for the treatment of mCRPC. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023. |
| Keywords: | bone metastasis; prostate; alpha particles; radium-223; metastatic castration-resistant prostate cancer; radiopharmaceutical therapy; mcrpc; [<sup>223</sup>ra]racl<sub>2</sub> |
| Book Title: | Radiopharmaceutical Therapy |
| ISBN: | 978-3-031-39004-3 |
| Publisher: | Springer |
| Publication Place: | Cham, Switzerland |
| Date Published: | 2023-01-01 |
| Start Page: | 387 |
| End Page: | 405 |
| Language: | English |
| DOI: | 10.1007/978-3-031-39005-0_19 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 19 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work